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A B S T R A C TObjective: To evaluate the precision of the predictive cost-effectiveness
assessment based on a phase 3 clinical trial with infliximab for the
treatment of rheumatoid arthritis in Swedish clinical practice. Methods:
Three patient cohorts were identified: the patients included in the
infliximab trial (ATTRACT), patients initially treated with infliximab
from a Swedish registry (STURE), a subset of these registry patients
meeting inclusion criteria for the ATTRACT trial was the third patient
cohort; two sets of assumptions in relation to the efficacy data were
evaluated: ‘‘ATTRACT’’ (efficacy data over the duration of the trial) and
‘‘STURE’’ (effectiveness data over 10 years). In addition, the impact of
including the placebo effect for the comparator was evaluated as a basis
for the calculation of cost-effectiveness by using a modeling approach. A
health economic model was utilized to estimate the cost per quality-
adjusted life-year (QALY) gained. Results: The results for the three
patient cohorts ranged from cost saving to a cost per QALY gained ofsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.002
ander@ki.se.
ondence to: Ingrid Lekander, Rostvingeva¨gen 33, 14h2,400 and h24,900 to h26,000 when the ATTRACT and STURE assump-
tions were used, respectively. Sensitivity analyses indicated that the
inclusion of placebo effect had the largest effect on the results, increas-
ing the cost per QALY gained to approximately h50,000 for all patient
cohorts. Conclusions: The treatment effect of infliximab measured in
clinical trials and clinical practice results in comparable cost-
effectiveness ratios, as calculated by using a modeling approach,
whereas the assumptions made in relation to the effectiveness data
and the chosen comparator have a large impact on the results. This
reinforces the value of early modeling studies based on randomized
clinical trial data, but assumptions made need to be carefully assessed.
Keywords: cost-effectiveness analysis, randomized clinical trial,
rheumatoid arthritis.
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At the time of reimbursement decisions for new interventions, cost-
effectiveness analyses have to be based on clinical trial data and
assumptions regarding future treatment patterns. To ensure internal
validity, and most often because of lack of appropriate data, the
placebo arm from the randomized clinical trial (RCT) is generally
used as the comparator. The precision of these cost-effectiveness
models can, however, seldom be rapidly verifiedwith clinical practice
data, as frequently the patients treated first with a new technology
are the most severe cases and thus not always comparable to the
RCT patients [1]. The ability of such models to predict the cost-
effectiveness of the evaluated treatment in clinical practice is also
debated because the controlled nature, short time, and patient
selection of the RCT do not cohere with a decision model [2]. In
addition, Philips et al. [3] argue that it is not reasonable to assume
that such a model will predict the future accurately because it can
only incorporate the data available at the time of conducting theanalyses. On the same note, Weinstein et al. [4] highlight that
predictive validation is reasonable only when there is consistency
of structure over time, which is seldom the case in health care.
Nevertheless, although a predictive validation of the actual model
may be of limited interest, it is of greater interest from both a
methodological and an investment perspective to evaluate the
impact of using clinical trial data when making decisions about
treatments in clinical practice. Do the highly selected patient
population from a clinical trial provide a good estimation of the
health economic outcomes in clinical practice? What lessons can be
learned to make more precise projections in future evaluations? In
recent years, drug reimbursement agencies have also increasingly
emphasized the necessity of follow-up studies based on real-world
evidence from clinical practice to facilitate reevaluation of funding
and positioning of treatments.
An area in which it is possible to perform such a predic-
tive validation of an early clinical trial assessment is for the
cost-effectiveness of biologic treatments for rheumatoid arthritisSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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inhibitors) have been available in Sweden for more than 10 years,
and patients are carefully followed in registries, providing an
opportunity to assess the cost-effectiveness of these treatments
in clinical practice. It has previously been estimated that a large
proportion, if not the majority, of the patients treated with TNF
inhibitors in clinical practice would not be eligible for inclusion in
the clinical trials [5,6]. It is therefore of interest to assess whether
treating a different patient group in clinical practice has an
impact on the estimated health economic consequences com-
pared with prior assessments of these treatments.
In this study, we evaluated the predictive validity of cost-
effectiveness models based on trial data in comparison to models
based on registry data, using the example of infliximab (INF). This
was the first anti-TNF introduced in Sweden, and there are
currently cost-effectiveness assessments based on both clinical trial
data [7,8] and data from clinical practice [9] available, using similar
models. The difference in the effectiveness of INF therapy between
RCT and clinical practice has previously been studied, although not
addressing the full health economic consequences of the different
patient cohorts. The previous studies have instead contributed with
enhanced knowledge of differences in Americal College of Rheu-
matology (ACR) response [5,6] and gain in quality-adjusted life-years
(QALYs) in the initial year of treatment [10] between the cohorts
included in the clinical trial and treated in clinical practice.
An early cost-effectiveness model based on the pivotal RCT
(ATTRACT) was published at the time of introduction [7,8], and the
model was updated by using data from the Stockholm biologics
registry (STURE) for the reevaluation of the use of biologics in RA
in Sweden [9]. In addition to the difference in the patient material,
the two evaluations used somewhat different assumptions in
relation to the effectiveness data in the health economic models.
The objective of this study was thus to evaluate the impact on the
cost-effectiveness results of using effectiveness estimates from
different patient cohorts from clinical trial and clinical practice as
well as to explore which assumptions related to the effectiveness
data (including comparator) most influence the cost-effectiveness
results. The impact of other model assumptions or model devel-
opment over time was not examined within the scope of this
article. For comparability, a similar method for matching patients
from clinical practice to the RCT cohort as used in previous
studies [5,6] is proposed in this current assessment.Methods
To assess the impact of different effectiveness data and the assump-
tions made in relation to these data, the following steps were taken:1. Identifying a suitable analytical framework: A previously
validated Markov model was used to estimate the cost per
QALY gained.2. Identifying effectiveness data and populating the model: The
data investigated were retrieved from an RCT and a registry,
providing three cohorts for comparison.
i. An RCT-based cohort
ii. A registry-based cohort
iii. A registry-based cohort with patients matching the RCT
cohort in terms of disease criteria (‘‘matched cohort’’)3.Fig. 1 – Simplified model structure.Identifying assumptions in relation to the effectiveness data
that may influence the results: As this is based on two
previously published health economic assessments, two sets
of assumptions were identified, necessitated by the different
nature of the two data sources.i. RCT-based assumptions
ii. Registry-based assumptions4. Performing analyses of a two-dimensional base case (three
cohorts in two sets of assumptions) and different alternative
scenarios to identify the drivers of the results. Probabilistic
sensitivity analyses (PSAs) were used to assess the precision
of the base-case scenario.
Analytical Framework
A cost-effectiveness model is needed to enable an evaluation of the
impact of any data in health economic terms. A previously validated
cost-effectiveness model of TNF-inhibitor treatment [7,9,11] was
therefore used for the computation of the cost per QALY gained
from treatment. By changing the patient cohort and assumptions
around the effectiveness data in the model, the impact of these
factors on the cost-effectiveness results was assessed.
The model used for this assessment was a previously validated
Markov cohort model programmed in TreeAge, originally developed
for the cost-effectiveness assessment of INF based on the ATTRACT
trial [7,8]. The model has thereafter been updated in other publica-
tions of TNF-inhibitor treatments [9,11], and the updated version
was used for this current assessment. The current model has five
health states based on functional status measured with the Health
Assessment Questionnaire (HAQ) (cutoffs at 0.6, 1.1, 1.6, and 2.1),
whereas the original model had six HAQ states (states five and six
combined into one in the updated version). The updated model also
includes a dimension of high and low disease activity (cutoff at
Disease Activity Scale [DAS28] 3.2) to each HAQ state, which was
not present in the original version. The model runs in annual cycles
for a time frame of 10 years. In each cycle of the model, patients can
transit to other health states (HAQ or DAS28), remain in the current
health state, or die. There is also a probability of discontinuing TNF-
inhibitor treatment in each cycle, and after discontinuation,
patients remain off treatment for the remainder of the simulation.
The TNF-inhibitor treatment evaluated is compared with a scenario
of no biologic treatment (either with or without placebo effect). A
simplified schematic picture of the model is presented in Figure 1.
The model was populated with data on direct and indirect costs
stratified by HAQ category and utilities stratified over HAQ cate-
gories and disease activity, in line with the publication of the STURE
model [9,11]. The results are presented in h2009-year values,
presented for the societal perspective of Sweden.
Patient Cohorts
The effect of using effectiveness data from clinical trials and
clinical practice data was explored by assessing the impact on
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 5 1 – 2 5 8 253cost-effectiveness of three different patient cohorts identified
from two different data sources. There are indications that a
large part of patients treated with biologic treatments for RA
would not have been eligible for inclusion in the RCTs [5,6]. Three
patient cohorts were therefore identified and compared: 1) the
RCT cohort from ATTRACT (‘‘RCT cohort’’) used in the first
evaluation of INF [4]; 2) all patients in the STURE registry
(‘‘registry cohort’’), identical to that used in Zink et al. [6]; and
3) a cohort extracted from the registry cohort that matches the
ATTRACT patients with regard to disease variables (‘‘matched
cohort’’).
The RCT cohort consisted of 287 patients from the pivotal RCT
randomized to INF plus methotrexate and 58 patients rando-
mized to placebo plus methotrexate every 8 weeks for 1 year. The
double-blinded period was followed by an open extension that
was not yet available at the time of the RCT-based evaluation.
Kobelt et al. [7] presented cost-effectiveness results comparing
INF treatment with placebo, using the treatment effect on
function (HAQ) directly from the trial for both groups. In the
absence of any data on longer term treatment, INF treatment was
stopped for all patients at the end of the double-blinded period.
To make the effectiveness data for this cohort fit the model used
for the evaluation, a new data extraction from the ATTRACT trial
was necessary to enable transition over disease activity (DAS28).
In addition, the HAQ progression was grouped into five HAQ
states instead of six as in the original publication to fit the model.
The registry cohort consisted of 637 patients who had initiated
treatment with INF as their first biologic therapy and were
followed for a mean duration of 5.1 years consistent with the
STURE-based publication [9]. The data were extracted in April
2008 and were estimated to represent around 90% of all patients
treated with INF in the Stockholm region at the time. Effectiveness
was estimated by extracting transition matrices for the first year
over the five HAQ health states and two states of disease activity
(DAS28). The average annual HAQ progression while remaining on
treatment after the initial year and a discontinuation function
were also extracted to assess the long-term effects of treatment,
extensively described in the previous publication [9].
To extract the matched cohort from the registry data, patients
meeting the ATTRACT inclusion criteria as closely as possibleTable 1 – Specification of base-case analyses and alterna
ATTRACT assumpt
effect d
Specification of base-case analyses
Comparator Placebo arm of ATTRAC
Discontinuation of treatment All discontinue treatme
Reverting to baseline HAQ at
discontinuation
Not assumed
Analyses of alternative scenarios (one by one)
Comparator Placebo effect excluded
progression on stand
instead
Cohort distribution over HAQ categories
at the start of therapy
Matched cohort
Registry cohort
Assumptions in relation to RCT data
after trial follow-up
Discontinuation rate
HAQ, Health Assessment Questionnaire; RCT, randomized clinical trial.were identified, limited by the data available in the registry data
set. The matched cohort was obtained from the patients who had
taken INF as their first biologic treatment (i.e., from the registry
cohort), using a similar method for matching as previously used
in an analysis of German registry data [6]. Matching was done on
the number of tender and swollen joints (Z4) as well as the
erythrocyte sedimentation rate (428 mm/h) and C-reactive pro-
tein levels (42 mg/dl) at the time point of initiating INF therapy,
in line with the criteria for inclusion in the ATTRACT trial [8]. In
the STURE registry, however, tender and swollen joints were
assessed in 28 joints whereas in the trial the 66/68 scale was
used. The cutoff for inclusion in the ATTRACT trial was set at 6 or
more tender and swollen joints [8]. Smolen et al. [12] demon-
strated that a cutoff of 6 in the 66/68 joint assessment is
approximately equivalent to 4 in the 28 joints count, whereby a
cutoff at 4 or more was used for selecting the patients from the
registry. The same methods for extracting transitions over HAQ,
DAS28, and discontinuation as for the registry cohort were
assessed.
Data-Specific Assumptions
The nature of the two original data sets (ATTRACT and STURE)
imposes different possibilities and challenges when assessed in
health economic analyses as one is from an RCT setting and one
clinical practice. The RCT data provided a placebo-controlled
comparator but with comparably short follow-up (1 year),
whereas the registry data provided long-term follow-up but no
comparator. The two previous publications therefore differed in
the assumptions made in relation to the effectiveness data
necessary to perform the cost-effectiveness analyses. For this
current assessment, it is hence essential to also investigate the
impact of the assumptions made, and therefore two sets of
assumptions were applied to the data of the three cohorts: 1)
ATTRACT assumptions and 2) STURE assumptions. The differ-
ences between these two are summarized in Table 1 (specifica-
tion of base-case analyses).
One large difference between the two sets of assumptions is
the comparator (i.e., the scenario with no biologic treatment). In
the ATTRACT assumptions, the placebo arm of the RCT is used astive scenarios.
ions related to
ata
STURE assumptions related to effect
data
T HAQ progression on standard therapy [9]
nt after 1 y A continuous discontinuation function
based on STURE data
Assumed
, assuming HAQ
ard therapy
Placebo effect included in the initial year
of therapy, then HAQ progression on
standard therapy [9]
Matched cohort
Registry cohort
HAQ progression of the matched cohort
Observed discontinuation rate instead of a
discontinuation function based on the
registry cohort
Table 2 – Patient characteristics.
Registry
cohort
Matched
cohort
RCT
cohort
Patients 637 306 340
Median age (y) 54.8 55.9 53.4
% female 77 77 77
Median disease
duration (y)
7.3 7.5 8.3
Mean HAQ score 1.4 1.5 1.7
Mean DAS28 score 5.5 6.0 NA
DAS28, Disease Activity Scale; HAQ, Health Assessment Question-
naire; NA, not applicable; RCT, randomized clinical trial.
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assumptions, an average disease progression without any effect
of treatment (real or placebo) is assumed in the absence of a
biologic treatment [13]. This may overestimate the rate of disease
progression in the absence of biologic treatment due to more
effective use of alternative treatments. If the rate of progression
in the comparator is overestimated, this will increase the mod-
eled gain from biologic treatment. Another large difference
between the two sets of assumptions is that in the ATTRACT
assumptions, all patients discontinue treatment after 1 year
whereas in the STURE assumptions, patients discontinue treat-
ment according to a discontinuation function (based on the
observed discontinuation in the STURE registry), implying that
some patients will stay on treatment for the whole simulation. In
addition, in the STURE assumptions, patients are assumed to
revert to their baseline HAQ and progress from there in the
absence of biologic treatment whereas this was not assumed in
the ATTRACT assumptions.
Extrapolation of RCT data
One challenge when combining the RCT cohort with the set of
STURE assumption is the limited duration of the clinical trial.
Therefore, some extrapolations of the RCT data were necessary to
allow treatment for longer than 1 year (as duration of the trial
data) in the model. It was assumed for the RCT cohort that the
DAS28 and HAQ levels reached after 1 year were maintained
while remaining on therapy. This may overestimate the effect of
therapy, but as the registry data suggest that patients only have a
small progression while remaining on therapy, the impact of this
extrapolation beyond trial follow-up is expected to be minor. It
was further assumed that after trial follow-up, the patients
discontinued therapy at the same rate as for the registry cohort.
Thus, the three cohorts were analyzed by using the two sets of
assumptions from the original publications of the ATTRACT and
STURE models in a base case to identify differences due to
treatment effect (comparison between cohorts given a specific
set of assumptions) and the assumptions made in relation to the
effectiveness data (comparison between the two sets of assump-
tions given a specific cohort).
Analyses of Alternative Scenarios
A number of alternative scenarios were tested in analyses to
identify the impact of the different components in the two sets of
assumptions made in relation to the effectiveness data (summar-
ized in Table 1). The impact of the comparator was tested by
incorporating the placebo effect as observed in the ATTRACT trial
in the scenarios using the STURE assumptions. It was then
assumed that patients in the comparator arm reverted to their
baseline HAQ after trial follow-up (the initial year of treatment)
and thereafter follow the progression without biologic treatment.
For the scenario using the ATTRACT assumptions, the placebo
effect was excluded, assuming the progression without biologic
treatment instead.
Extrapolations of the RCT data after trial follow-up necessary
to fit the STURE assumptions were also tested. An HAQ progres-
sion equivalent to the observed long-term progression from the
matched cohort was therefore applied instead of assuming a
stable HAQ while remaining on therapy. The observed disconti-
nuation rate during the trial was also extrapolated for all
subsequent years instead of using the discontinuation function
based on the registry cohort.
The distribution over HAQ categories at the initiation of
therapy for the base case was taken from the RCT cohort. This
was tested in alternative analyses by using the distribution from
the two registry-based cohorts instead. In addition, the directly
observed discontinuation rates of the two registry cohorts wereapplied in the model in a separate analysis instead of using a
discontinuation function. Also, one analysis was performed in
which a combination of assumptions was altered at the same
time, that is, including the placebo effect of the comparator,
using the observed discontinuation rates instead of a disconti-
nuation function as well as using the HAQ progression after trial
follow-up as in the registry cohort.
PSA
PSAs of 1000 runs were performed to assess the precision in the
effectiveness data in the six base-case scenarios. Dirichlet distribu-
tions were assigned to the HAQ transitions in the initial year as it is
suitable to estimate the uncertainty in probabilities when using
rival events (five mutually exclusive HAQ events in the model), and
beta distributions were assigned to the DAS28 transitions as it is
suitable when using probabilities between 0 and 1.Results
Patient Cohorts
Of the 637 patients in the STURE registry data set, 48% met the
ATTRACT inclusion criteria and were included in the matched
cohort. The baseline characteristics of these patients as well as
the RCT and registry cohorts are presented in Table 2. It is
noticeable that the patients from the registry (both matched
and registry cohorts) differed slightly from the RCT cohort in the
demographic data points through lower median disease duration
at the start of therapy and the initiation of therapy at a lower
HAQ score than those included in the ATTRACT clinical trial.
Cost-Effectiveness Results
The base-case results from the six scenarios explored within this
assessment are presented in Table 3. The difference in results
between the three INF patient cohorts applied in the model was
small, and the cost per QALY gained compared with no biologic
treatment (placebo or standard therapy depending on the set of
assumption) fell within a small range when applying the same
assumptions to the three cohorts. The chosen set of assumptions
had a large impact on the results. The STURE assumptions
increased the cost per QALY gained compared with when the
ATTRACTassumptions were utilized, which was mainly driven by
the increased persistence on therapy (increasing both costs and
QALYs, although not proportionally).
The results of the alternative scenarios and exploration of
different assumptions in relation to the effectiveness data are
presented in Table 4. Assumptions made after trial follow-up of
the RCT cohort (to allow for treatment duration longer than 1
year as in the STURE assumptions) had a limited impact on the
Table 3 – Cost-effectiveness results for the base case (h2009).
Costs Incremental costs QALYs QALYs gained Cost/QALY gained
ATTRACT assumptions
Comparator (placebo RCT) 109,009 3.682
INF RCT cohort 109,972 963 4.166 0.484 1,990
INF Matched cohort 108,912 97 4.221 0.539 Cost saving
INF Registry cohort 110,166 1,158 4.165 0.483 2,397
STURE assumptions
Comparator (standard therapy) 119,904 3.226
INF RCT cohort 137,897 17,993 3.948 0.722 24,921
INF Matched cohort 138,561 18,657 3.943 0.717 26,021
INF Registry cohort 138,581 18,677 3.950 0.724 25,797
INF, infliximab; QALY, quality-adjusted life-year; RCT, randomized clinical trial.
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in registry cohort’’). Initial distribution of the cohorts over HAQ
categories at the start of therapy and applying the observed
dropout rates from the registry data instead of a discontinuation
function also had minor effects on the results.
The choice of progression for the comparator (i.e., with or
without placebo effect), however, had a large impact on the results.
When the placebo effect during the initial year was included for the
comparator arm in the STURE assumptions, the cost per QALY
gained increased significantly to approximately h50,000 for all three
patient cohorts. On the same reasoning, excluding the placebo
effect (assuming standard treatment as in the STURE assumptions)
for the comparator in the ATTRACT assumptions made the results
for all three cohorts cost saving. Combining the placebo effect in the
comparator with observed discontinuation rates and the HAQ
progression from the registry cohort for the RCT cohort after trial
follow-up resulted in larger differences between the two registry-
based cohorts and the RCT cohort.
PSA
The results from the PSAs are presented in Figure 2. The results
indicate that the uncertainty in the effectiveness estimates (HAQTable 4 – Cost per QALY gained compared with no biolog
Registry
cohort
ATTRACT assumptions
Base case 2,397
Excluding placebo effect Cost saving
Matched cohort initial distribution 1,741
Registry cohort initial distribution 2,243
STURE assumptions
Base case 25,797
Placebo effect in comparator 50,234
HAQ progression after trial follow-up as in
Registry cohort
25,797
Observed discontinuation rates 30,383
Matched cohort initial distribution 26,350
Registry cohort initial distribution 26,568
Placebo effect, HAQ progression after trial
follow-up, and observed discontinuation rates
55,665
HAQ, Health Assessment Questionnaire; QALY, quality-adjusted life-yea
For the RCT cohort, this means that the observed discontinuation
discontinuation rate in subsequent years.and DAS progression) has a larger impact in the scenario with the
ATTRACT-based assumptions than in the scenario with the
STURE-based assumptions by providing wider confidence inter-
vals. The results confirm that there is no significant difference
between the three cohorts given one set of assumptions, but
there is a significant difference in the results between the
ATTRACT and STURE sets of assumptions.Discussion
Our analysis found that 48% of the patients initiating INF as their
first TNF-inhibitor treatment in the STURE registry data set met
the ATTRACT inclusion criteria. This is in line with other studies
in which it has been demonstrated that 33% to 48% of the patients
treated with INF in clinical practice would be eligible for inclusion
in the clinical trials [5,6]. Although there is a discrepancy in the
patient cohorts included in the RCT and treated in clinical
practice, this study has indicated that the effect from treatment
for these different cohorts does not translate into any difference
in the cost-effectiveness of INF treatment. The assumptions made
in relation to the effectiveness data, however, did have a sig-
nificant impact on the results, producing higher cost per QALYic treatment for alternative scenarios (h2009).
Patient cohort
Matched
cohort
RCT
cohort
Range in cost per
QALY gained
Cost saving 1,990 Cost saving  2,397
Cost saving Cost saving Cost saving
Cost saving 681 Cost saving  1,741
493 1,736 493–2,243
26,021 24,921 24,921–26,021
50,933 49,015 49,015–50,933
26,021 25,646 25,646–26,021
29,940 30,529 29,940–30,529
26,495 25,270 25,270–26,495
27,289 25,886 25,886–27,289
55,059 47,321 47,321–55,665
r; RCT, randomized clinical trial.
rate during the ATTRACT trial was assumed to be the annual
Fig. 2 – 95% CI from probabilistic sensitivity analyses.
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the placebo effect from the clinical trial. Although the STURE
(registry)-based assumptions provided higher gains in QALYs than
did the ATTRACT (RCT)-based assumptions, the incremental costs
also increased, mainly because of a longer treatment duration.
The costs increased to a higher degree than the QALYs gained,
providing higher incremental cost-effectiveness ratios. The largest
gain from treatment is during the first year; thereafter, the
marginal QALY gain is small as patients are maintained in a
better health state although the marginal cost is close to the full
treatment cost.
One limitation of early modeling and the use of it as a
prognostic tool is the limited scope of the RCT data. As follow-
up time is generally a year or two in an RA-treatment trial,
assumptions are necessary to make projections after trial follow-
up to allow for an analysis closer to the expected use in clinical
practice. Some of the assumptions applied to the RCT cohort in
this assessment build on experiences from clinical practice,
although this is most likely unknown at the time of actually
performing an RCT-based health economic evaluation. Any
assumptions made regarding the time after trial follow-up will
impose an uncertainty to the results. For example, as an RCT is a
controlled environment, the discontinuation rate is likely to be
smaller in the RCT than in clinical practice, and so using any
discontinuation rate from the RCT would most likely overesti-
mate the persistence of therapy, especially in the initial years of
treatment. Still, sensitivity analyses of the discontinuation rates
used in this assessment indicated that the difference between
extrapolating the discontinuation rate from the trial and using
the observed discontinuation rate from the registry did not have
any major impact on the cost-effectiveness results. This study
has further demonstrated that extrapolating data beyond the trial
instead of just analyzing the duration of the trial has a large
effect on the results and that it is essential to conduct extensive
sensitivity analysis to investigate the impact of the assumptions
made. Still, extrapolation of the RCT effectiveness data beyond
trial follow-up provided good prediction of the costs and QALYs
associated with INF treatment in clinical practice. The incre-
mental results, however, were sensitive to the comparator used.
Early RCT-based assessments often use the placebo effect for the
comparator, which demonstrates high internal validity to the
efficacy data. It may be argued that the placebo-controlled effect
from treatment, the true effect, is what society should be payingfor. However, including the placebo effect decreases the modeled
gain from treatment and it is not a realistic treatment alternative
in clinical practice. In this sense, it is instead more reasonable for
society to pay for the incremental effect compared with the best,
clinically relevant alternative. At the time of market introduction,
however, the only other alternative to using the placebo effect
may be to base the comparator on other publications (if no
registry data are available) with increased uncertainty around
the progression estimates of the comparator and hence also the
gain of treatment. There are also problems with identifying data
for the right comparator when using registry-based effectiveness
data to populate a cost-effectiveness model. Historical registry
data may serve as an alternative (if available) although there may
be other advances in alternative treatments over time, altering
the true alternative to the new treatment intervention. In addi-
tion, when a new intervention has become the new standard
treatment, the alternative is simply no longer available in clinical
practice as those patients not receiving the new treatment differ
in some way (disease characteristics, intolerance, etc.) from those
who receive the treatment. The progression of treatment the
time before initiating therapy could also serve as a comparator,
although there is no certainty that this progression would persist
in the future in the absence of treatment. Nevertheless, the
results from this study have highlighted the large impact of the
progression for the comparator, whereby it must be highly
scrutinized whichever data source is used.
The original published ATTRACT analysis of INF resulted in a
cost per QALY gained of h3800 (An exchange rate of 9.3 SEK/h was
applied in line with the original publication, and inflated to 2009-
year values.) [7]. The findings of this current study indicate that
the different utility data and the addition of the disease activity
component when applying the ATTRACT assumptions decreased
the cost per QALYs gained from INF treatment to approximately
h2000. Hence, this difference in model structures did not have
any major impact on the results. Still, the results of this assess-
ment have shown that the assumptions made in the health
economic model with regard to the comparator (i.e., including the
placebo effect) and extrapolation beyond trial follow-up had a
large impact on the results. These results highlight the necessity
of continuous follow-up of the prognostic models that are used in
health economic evaluations to provide the best assumptions
and model structure available for a good prognosis of the health
economic consequences.
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and clinical practice has previously been studied, although not
addressing the full health economic consequences of the different
patient cohorts. For comparability, a similar method for matching
patients to the RCT cohort as used in previous studies [5,6] was
used in this current assessment, although investigating the
difference in cost-effectiveness results of the different patient
cohorts instead of ACR response. Zink et al. [6] have indicated that
patients treated with INF in clinical practice had a similar ACR
response as indicated in the ATTRACT trial. It has further been
demonstrated that patients in clinical practice classified as
ineligible for RCT inclusion were found to have a lower response
than eligible patients [5,6]. In a study by Farahani et al. [10], it was
demonstrated that an RCT cohort had a higher gain in QALYs than
did a registry-based cohort. This was not confirmed in this current
assessment as no large difference in results between the different
patient cohorts investigated was identified when considering only
the effectiveness data. Instead it was found that patients treated
in Swedish clinical practice (both the matched and overall cohort)
had a similar gain in QALYs as the RCT cohort when the same
assumptions were used, in line with the indications of Zink et al.
[6]. It should also be noted that the effectiveness data for the RCT
cohort include nonresponders, decreasing the modeled gain of
treatment. The nonresponders would drop out or switch treat-
ment in clinical practice and are hence not included in the
cohorts observed in clinical practice. If this was corrected for,
the RCT cohort would most likely have a larger gain in QALYs,
although the magnitude of this is unknown. Still, the current
results suggest that the prognostic value of INF treatment in the
RCT-based evaluation is in line with Swedish clinical practice and
that the differences in the three patient cohorts did not translate
into any major difference in the health economic results when
evaluating the effect of therapy.
Using observed, long-term real-world cost-effectiveness data
would have been the preferred method to study the predictive
validity of cost-effectiveness models. In the absence of such
coherent data and out of interest from a methodological point
of view, however, we chose to investigate the predictability of the
cost-effectiveness in clinical practice of an early RCT-based
model by using a modeling approach instead. The full predictive
validity of the RCT-based model can therefore not be assessed by
using this approach because modeling in itself is no absolute
truth but holds a certain degree of uncertainty in its own nature.
Nevertheless, this study has shown that although there are some
differences in the measured effect of treatment between the
patient cohorts in clinical trials and clinical practice, this did not
translate into any major differences in the cost-effectiveness
results when the same assumptions and comparator were used.
The main drivers of the results, however, were instead the
assumptions made in relation to the effectiveness data, that is,
treatment duration and extrapolating data beyond trial follow-up
as well as the choice of comparator (with or without placebo
effect). It can therefore be concluded that the effectiveness data
for INF from the ATTRACT trial provided a good prognosis of the
modeled cost-effectiveness in clinical practice, although the
assumptions made in relation to the RCT data resulted in
significantly lower results. Nevertheless, the results reinforce
the value of early modeling studies for reimbursement decisions.
In addition, it can be recommended for chronic progressive
diseases such as RA to extrapolate beyond trial follow-up to
increase the precision in the prognosis of the health economic
consequences in clinical practice. The health economic results,
however, are sensitive to assumptions and comparators chosen
whereby any early modeling has to be carefully scrutinized.
As discussed above, it is hard to assess the ‘‘true’’ comparator
in clinical practice, whereby any analysis claiming to mirror
clinical practice will include some level of uncertainty. Onelimitation to this analysis was that we did not include cycling
of biologics after the discontinuation of the first biologic treat-
ment. The reason to this is twofold: first, the RCT data provided
data only for a first biologic treatment whereby this is the base of
the comparison. In addition, cycling of biologics was not part of
the registry-based publication either. Second, as the same data
on cycling biologics would be used for all cohorts, it would not
impact the conclusions, although it would have an impact on the
level of costs and utilities. Furthermore, this study has not
assessed other variations in daily clinical practice such as
changes in dosing patterns and dose titrations, co-medications,
adherence to clinical guidelines, and other external factors.
These factors may have an impact on the modeled results, but
examining this was not part of the scope of this study. An update
of this analysis may also be warranted only using registry data for
patients initiating treatment in more recent years as the patients
first treated with biologics were in a worse health state than
those initiating treatment in more recent years, potentially
affecting the cost-effectiveness of these treatments. Another
limitation to this study was that we did not have access to the
patient-level data from the ATTRACT trial, limiting the possibi-
lities for a more precise estimation of HAQ and DAS28 progres-
sion and thereby a comparison of progression over time between
the three cohorts. The analysis was therefore conducted on
movements over HAQ and DAS28 categories as specified by the
health economic model.
There are pros and cons with registry data and RCT data, and
views about which data source is more reliable and more
appropriate in health economic analyses are not coherent. This
study has shown that the effectiveness data from two different
types of sources give comparable incremental cost-effectiveness
estimates when the same comparator is used and the same
assumptions are applied to the data. This is demonstrated with
the example of INF treatment for RA. For future research, similar
assessments in other therapy areas are warranted before any
general conclusions of early cost-effective modeling can be
drawn. Source of financial support: The study was supported by
a grant from Schering-Plough AB (MSD).
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